Semaglutide

Product Specifications

• CAS: 910463-68-2
• Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 diacid-γGlu-OEG-OEG linker)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Mass: 4113.58 Da
• Purity: 99%+ (verified by HPLC)
• Appearance: White to off-white lyophilized powder
• Form: Lyophilized (freeze-dried)

Storage

Semaglutide vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted semaglutide should be kept at -20°C for long-term storage or 2-8°C for short-term use. Does semaglutide expire? Once reconstituted with bacteriostatic water, semaglutide should be stored at 2-8°C and used within 28-30 days for optimal peptide stability. Do not freeze reconstituted solutions. Always follow proper aseptic technique and storage guidelines to maintain product integrity for research applications.

Solubility

Semaglutide is soluble in bacteriostatic water and sterile saline. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

Semaglutide is intended for research purposes only and is not approved for human use.

How Does Semaglutide Work? GLP-1 Receptor Mechanism of Action

• Semaglutide is a modified GLP-1 receptor agonist with two structural differences from native GLP-1: a substitution at position 8 (alanine replaced by alpha-aminoisobutyric acid) that confers resistance to DPP-4 enzymatic degradation, and a C18 fatty diacid chain at K26 via a hydrophilic spacer that enables reversible albumin binding and extends half-life to approximately 168 hours (7 days).
• GLP-1 receptors are expressed across multiple organ systems including pancreatic beta cells, the gastrointestinal tract, the cardiovascular system, and the central nervous system. Semaglutide activates these receptors to suppress glucagon secretion, slow gastric emptying, stimulate glucose-dependent insulin release, and reduce net energy intake through appetite signaling pathways.
• Research in rodent models confirms that central GLP-1 receptor activation is both necessary and sufficient to produce the body weight reduction associated with GLP-1 agonism.

Semaglutide Weight Loss Research: Body Composition and Appetite Suppression

• Semaglutide for weight loss is the most extensively studied application of this compound. Research in rodent obesity models demonstrates that GLP-1 receptor agonism reduces body weight through reduced energy intake via appetite suppression and delayed gastric emptying, which slows nutrient absorption and prolongs postprandial satiety signals.
• Semaglutide weight loss dosage chart data from preclinical studies shows clear dose-dependent responses across weekly administration protocols, with measurable body weight reductions beginning at low doses in mouse models and maximum effects at higher doses. Weekly dosing produces sustained receptor activation consistent with the compound's pharmacokinetic profile.
• Semaglutide before and after body composition analyses in preclinical obesity models demonstrate statistically significant reductions in total fat mass over 4-12 week research periods, with lean mass largely preserved, distinguishing GLP-1 agonist-driven weight loss from pure caloric restriction models where lean mass loss is more pronounced.

Semaglutide vs Tirzepatide: GLP-1 and Dual Agonist Mechanism Comparison

• Semaglutide vs tirzepatide is the central mechanistic comparison in current incretin peptide research. Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist that simultaneously activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1 receptor via a single unimolecular peptide.
• The difference between semaglutide and tirzepatide in preclinical research models shows that dual receptor activation produces greater reductions in body weight and fat mass than GLP-1 agonism alone. GIPR activation on adipocytes and in the central nervous system contributes additional lipolytic and anorectic effects beyond what the GLP-1 pathway achieves independently.

Semaglutide Dosage for Research

Semaglutide dosage used in preclinical research varies by study design, animal model, and administration route. Common dosing protocols in published literature include:

• Subcutaneous injection: 3–30 nmol/kg (approximately 12–124 mcg/kg) body weight, administered once weekly. The most common route in published metabolic and obesity research, covering the dose-response curve from threshold to near-maximal effect in rodent models.
• Dose escalation protocols: Research typically begins at the low end of the range and escalates over 2–4 weeks to minimise gastrointestinal effects at the model level, mirroring standard preclinical titration methodology.
• Intraperitoneal injection: Used in some pharmacokinetic and mechanistic studies for consistent systemic delivery, particularly in rodent models investigating central appetite suppression pathways.

Semaglutide dosage frequency is once weekly, reflecting its approximately 7-day half-life. Statistically significant body composition changes typically require 4–12 weeks of sustained dosing. A peptide calculator can help scale published nmol/kg or mcg/kg doses to a given research subject weight.

Research Protocol Notes

This product is intended for research purposes only and should not be used for human consumption. It is strictly designated for laboratory and scientific use by qualified professionals. Common research applications include:

• In vitro cellular assays and cell culture studies
• Receptor binding profiling and signaling pathway analysis
• Analytical reference standards for High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS)
• Approved in vivo animal modeling to investigate physiological mechanisms and metabolic responses